Stock traders buy large volume of put options on organogenesis (NASDAQ: ORGO)
Organogenesis Holdings Inc. (NASDAQ: ORGO) saw unusual options trading on Friday. Equity investors bought 7,023 puts on the company. This is an increase of 879% over the typical daily volume of 717 puts.
In other news, the 2016 main shareholder of Organo 10-Year Grat U / Gn bought 25,000 shares of the company in a transaction dated Thursday, November 18. The shares were purchased at an average cost of $ 9.93 per share, for a total transaction of $ 248,250.00. The purchase was disclosed in a legal file with the Securities & Exchange Commission, which is available through this link. In the past 90 days, insiders have purchased 30,300 shares of the company valued at $ 299,793. Company insiders own 34.20% of the company’s shares.
Several institutional investors have recently bought and sold ORGO shares. PNC Financial Services Group Inc. acquired a new stake in Organogenesis during the second quarter valued at approximately $ 34,000. Ameritas Investment Partners Inc. increased its position in Organogenesis by 47.3% during the second quarter. Ameritas Investment Partners Inc. now owns 2,990 shares of the company valued at $ 50,000 after purchasing an additional 960 shares during the last quarter. Royal Bank of Canada increased its position in Organogenesis by 25.9% during the second quarter. Royal Bank of Canada now owns 4,179 shares of the company valued at $ 69,000 after purchasing an additional 861 shares in the last quarter. Advisor Group Holdings Inc. increased its position in Organogenesis by 24.9% during the second quarter. Advisor Group Holdings Inc. now owns 4,630 shares of the company valued at $ 78,000 after purchasing 924 additional shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Organogenesis during the second quarter for an amount of approximately $ 98,000. 38.41% of the shares are currently held by institutional investors.
Several analysts recently published reports on the company. SVB Leerink lowered its organogenesis price target from $ 26.00 to $ 20.00 and set an “outperform” rating on the stock in a report released on Wednesday, November 10. Zacks Investment Research downgraded Organogenesis from a “buy” rating to a “keep” rating in a report released Wednesday, October 13. Finally, BTIG Research assumed coverage of organogenesis in a Friday, December 10 report. They set a “buy” rating and a target price of $ 24.00 for the stock. One investment analyst rated the stock with a conservation rating and three gave the stock a buy rating. According to MarketBeat, Organogenesis currently has an average rating of “Buy” and a consensus target price of $ 21.50.
NASDAQ: ORGO traded up $ 0.42 on Friday, reaching $ 9.49. The company’s shares had a trading volume of 5,008,695 shares, compared to its average volume of 1,059,393. The company has a current ratio of 2.62, a quick ratio of 2.25 and a ratio of debt of 0.38. The stock has a fifty-day moving average of $ 10.59 and a two-hundred-day moving average of $ 13.85. The company has a market cap of $ 1.22 billion, a P / E ratio of 20.07 and a beta of 1.72. Organogenesis has a one-year low of $ 5.77 and a one-year high of $ 24.34.
Organogenesis (NASDAQ: ORGO) last released its quarterly earnings data on Tuesday, November 9. The company reported earnings per share (EPS) of $ 0.09 for the quarter, beating the consensus estimate of $ 0.06 by $ 0.03. Organogenesis had a return on equity of 36.76% and a net margin of 13.82%. The company posted revenue of $ 113.75 million for the quarter, compared to analysts’ estimates of $ 112.10 million. In the same quarter of the previous year, the company achieved earnings per share of $ 0.19. As a group, sell-side analysts predict that Organogenesis will show 0.4 BPA for the current year.
Organogenesis Company Profile
Organogenesis Holdings, Inc. is a regenerative medical company. It is focused on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.
Read more: Stocks increase dividends
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]
Should You Invest $ 1,000 in Organogenesis Now?
Before you consider organogenesis, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of … and Organogenesis was not on the list.
While Organogenesis currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here